Tahir Amin started out wanting to play professional football in England. He found law instead, and specifically intellectual property law in the early 1990s, when the field was still new enough to feel cutting edge. After a decade of commercial IP practice in the UK and the US, he moved to India in 2004 to understand what the new global IP rules were doing to the people they never accounted for. He arrived just as India was being required to comply with WTO patent rules that would affect access to HIV medicines costing tens of thousands of dollars a year. That experience led him to co-found I-MAC in 2006.
In this conversation, Amin walks Rubino through the political economy of drug patents: how neoliberal policy from the late 1970s onward handed control of publicly funded research to private companies, how those companies built out sprawling patent portfolios to delay generic competition, and how the word "innovation" became a shield against any real scrutiny. He also talks about what I-MAC's work has achieved, the blowback it has faced, and why he considers himself a "cynical optimist" who believes the long game is the only game worth playing.
Patent stacking is the norm, not the exception. Novo Nordisk filed more than 320 patent applications around the single active ingredient in the Ozempic family of drugs.
1 in 3 Americans are skipping doses or cutting pills to afford their medications. This is a policy problem rooted in decisions made over the past four decades.
The word "innovation" replaced "invention" deliberately around 1976–77, allowing corporations to privatize public-funded knowledge and charge rent for it.
I-MAC's public patent database puts the evidence on the table. The pharma industry attacks the messenger rather than engaging the data.
Incrementalism is the system's release valve. Real change requires playing the long game, not chasing the next quick win.
Pharma Monopoly: The Battle for the Future of Medicines by Tahir Amin (book)
pharmaceutical patents, drug pricing, patent monopoly, medicine access, IP law, I-MAC, Tahir Amin, patent stacking, Ozempic patents, Novo Nordisk, innovation myth, neoliberalism, affordable medicine, generic drugs, biosimilars, patent reform, WTO patent law, drug affordability, pharma policy, Jabot podcast
| 00:08:18 - 00:09:16 | Amin explains the founding of I-MAC and the need to challenge systems treating public knowledge as monopoly property. |
| 00:12:49 - 00:13:33 | The survey data: 1 in 3 Americans are skipping or rationing medications, a Western problem as much as a global one. |
| 00:16:12 - 00:16:55 | Novo Nordisk's 320+ patent applications on the Ozempic active ingredient, and how that data changed the Congressional conversation. |
| 00:21:52 - 00:24:54 | The linguistic shift from "invention" to "innovation" after the late 1970s, and why the distinction matters for policy. |
| 00:30:27 - 00:31:32 | Why incrementalism is the system's release valve, and the case for committing to real, structural change over the long run. |
